Brandon A Mahal1, Ayal A Aizer2, David R Ziehr1, Andrew S Hyatt3, Jesse D Sammon4, Marianne Schmid5, Toni K Choueiri6, Jim C Hu7, Christopher J Sweeney6, Clair J Beard3, Anthony V D'Amico3, Neil E Martin3, Simon P Kim8, Quoc-Dien Trinh5, Paul L Nguyen9. 1. Harvard Medical School, Boston, MA. 2. Harvard Radiation Oncology Program, Boston, MA. 3. Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 4. Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI. 5. Division of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston MA. 6. Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 7. Department of Urology, UCLA Medical Center, Los Angeles CA. 8. Department of Urology, Cancer Outcomes and Public Policy Effectiveness Research Center, Yale University, New Haven, CT. 9. Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: pnguyen@LROC.harvard.edu.
Abstract
OBJECTIVE: To determine whether African Americans (AAs) with intermediate- to high-risk prostate cancer (PCa) receive similar treatment as white patients and whether any observed disparities are narrowing with time. METHODS: We used Surveillance, Epidemiology, and End Results to identify 128,189 men with localized intermediate- to high-risk PCa (prostate-specific antigen ≥10 ng/mL, Gleason score ≥7, or T stage ≥T2b) diagnosed from 2004 to 2010. We used multivariate logistic regression analyses to determine the impact of race on the receipt of definitive treatment. RESULTS: AA men were significantly less likely to receive curative-intent treatment than white men (adjusted odds ratio [AOR], 0.82; 95% confidence interval [CI], 0.79-0.86; P <.001). There was no evidence of this disparity narrowing over time (Pinteraction 2010 vs 2004 = .490). Disparities in the receipt of treatment between AA and white men were significantly larger in high-risk (AOR, 0.60; 95% CI, 0.56-0.64; P <.001) than in intermediate-risk disease (AOR, 0.92; 95% CI, 0.88-0.97; P = .04; Pinteraction <.001). After adjusting for treatment, demographics, and prognostic factors, AA men had a higher risk of prostate cancer-specific mortality (adjusted hazard ratio, 1.12; 95% CI, 1.01-1.25; P = .03). CONCLUSION: AA men with intermediate- to high-risk PCa are less likely to be treated with curative intent than white men. This disparity is worse in high-risk disease and is not improving over time. Factors underlying this treatment disparity should be urgently studied as it is a potentially correctable contributor to excess PCa mortality among AA patients.
OBJECTIVE: To determine whether African Americans (AAs) with intermediate- to high-risk prostate cancer (PCa) receive similar treatment as white patients and whether any observed disparities are narrowing with time. METHODS: We used Surveillance, Epidemiology, and End Results to identify 128,189 men with localized intermediate- to high-risk PCa (prostate-specific antigen ≥10 ng/mL, Gleason score ≥7, or T stage ≥T2b) diagnosed from 2004 to 2010. We used multivariate logistic regression analyses to determine the impact of race on the receipt of definitive treatment. RESULTS: AA men were significantly less likely to receive curative-intent treatment than white men (adjusted odds ratio [AOR], 0.82; 95% confidence interval [CI], 0.79-0.86; P <.001). There was no evidence of this disparity narrowing over time (Pinteraction 2010 vs 2004 = .490). Disparities in the receipt of treatment between AA and white men were significantly larger in high-risk (AOR, 0.60; 95% CI, 0.56-0.64; P <.001) than in intermediate-risk disease (AOR, 0.92; 95% CI, 0.88-0.97; P = .04; Pinteraction <.001). After adjusting for treatment, demographics, and prognostic factors, AA men had a higher risk of prostate cancer-specific mortality (adjusted hazard ratio, 1.12; 95% CI, 1.01-1.25; P = .03). CONCLUSION: AA men with intermediate- to high-risk PCa are less likely to be treated with curative intent than white men. This disparity is worse in high-risk disease and is not improving over time. Factors underlying this treatment disparity should be urgently studied as it is a potentially correctable contributor to excess PCa mortality among AA patients.
Authors: Mohammad Aslam Khan; Girijesh Kumar Patel; Sanjeev Kumar Srivastava; James Elliot Carter; Jennifer Young Pierce; Rodney Paul Rocconi; Seema Singh; Ajay Pratap Singh Journal: Cancer Health Disparities Date: 2019-08-19
Authors: Mohamed H Kamel; Milan Bimali; Mahmoud I Khalil; Ehab Eltahawy; LJoseph Su; Nabil K Bissada; Rodney Davis Journal: Int Urol Nephrol Date: 2019-03-06 Impact factor: 2.370
Authors: Andrew T Wong; Joseph J Safdieh; Justin Rineer; Joseph Weiner; David Schwartz; David Schreiber Journal: Int Urol Nephrol Date: 2015-09-02 Impact factor: 2.370
Authors: Maria C Velasquez; Felix M Chinea; Deukwoo Kwon; Nachiketh Soodana Prakash; Marcelo P Barboza; Mark L Gonzalgo; Chad R Ritch; Alan Pollack; Dipen J Parekh; Sanoj Punnen Journal: Urology Date: 2018-04-06 Impact factor: 2.649
Authors: Brittaney-Belle E Gordon; Ramsankar Basak; William R Carpenter; Deborah Usinger; Paul A Godley; Ronald C Chen Journal: Cancer Date: 2019-01-29 Impact factor: 6.860
Authors: Robert T Dess; Holly E Hartman; Brandon A Mahal; Payal D Soni; William C Jackson; Matthew R Cooperberg; Christopher L Amling; William J Aronson; Christopher J Kane; Martha K Terris; Zachary S Zumsteg; Santino Butler; Joseph R Osborne; Todd M Morgan; Rohit Mehra; Simpa S Salami; Amar U Kishan; Chenyang Wang; Edward M Schaeffer; Mack Roach; Thomas M Pisansky; William U Shipley; Stephen J Freedland; Howard M Sandler; Susan Halabi; Felix Y Feng; James J Dignam; Paul L Nguyen; Matthew J Schipper; Daniel E Spratt Journal: JAMA Oncol Date: 2019-07-01 Impact factor: 31.777
Authors: Daniella Klebaner; P Travis Courtney; Isla P Garraway; John Einck; Abhishek Kumar; Maria Elena Martinez; Rana McKay; James D Murphy; Humberto Parada; Ajay Sandhu; Tyler Stewart; Kosj Yamoah; Brent S Rose Journal: J Natl Cancer Inst Date: 2021-10-01 Impact factor: 11.816